However, approximately half of all HER2/neu-overexpressing breast cancer patients do not respond to trastuzumab-containing therapy [15], and only 25% of patients respond when trastuzumab is given as a first-line mono-therapy [16]. Here, ERBB2 is linked to breast cancer.